Web24 okt. 2024 · About KSQ-4279 and USP1 Inhibition. USP1 is a member of the ubiquitin-specific processing (UBP) family of proteases. USP1 regulates DNA damage response … WebKSQ-4279 is the first selective de-ubiquitinase inhibitor into the clinic, he adds. The drug is in phase I, as monotherapy and in combination with various agents including PARP inhibitors. Tango is also advancing a USP1 inhibitor towards the clinic. Genetics versus pharmacology As interest in synthetic lethality opportunities

KSQ Therapeutics Announces First Patient Dosed in Phase …

Web19 apr. 2024 · The drug is currently in phase 1 clinical development as both a monotherapy and in combination with other agents, including an SHP2 inhibitor. EZM0414, a first-in-class, potent, selective, orally bioavailable small molecule inhibitor of the enzymatic activity of SETD2 to target B-cell malignancies, was also discussed during the presentation. Web22 mrt. 2024 · First disclosure of KSQ-4279 structure, a potent and selective USP1 inhibitor KSQ-4279 has a unique mode of allosteric binding to USP1 and a high degree of selectivity over other family members ryff\u0027s model

KSQ Therapeutics : Announces First Patient Dosed in Phase 1 …

Web15 jun. 2024 · We developed KSQ-4279, a potent, highly selective inhibitor of USP1. KSQ-4279 was active in cells, leading to the accumulation of mono-ubiquitinated substrates of USP1 and inhibited the proliferation of … Web22 mrt. 2024 · KSQ-4279 is a first-in-class small molecule targeting USP1, a protein regulating DNA damage response (DDR). USP1 was identified by KSQ’s … is facebook safe for 13 year olds